Clinical Trial Update: Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP798 to rituximab in non-Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• ABP798 (null)
• Rituximab (rituximab)

Snippet

Sponsor: Amgen | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2020-08-18